# MANGOCEUTICALS (MGRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MGRX
## Company Profile
- Ticker: MGRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Digital Health
## Stock Data
- Close: 0.3903 USD
- Market cap: 6575122.626 USD
- Last updated: 2026-09-03
## Business Overview
Mangoceuticals is a consumer-facing healthcare company focused on men’s health, telehealth, and branded wellness products. Its story is centered on direct-to-consumer distribution rather than classic biotech innovation.
## Why The Stock Is Moving

As of Sep 3, 2026, MGRX closed up 1.64% at $0.3903. No new same-company headline was identified in the current news window.

## Geographic Base

Mangoceuticals is headquartered in the United States and listed on NASDAQ. It sits in consumer health and telehealth rather than biotechnology.

## Business Model

The business model depends on brand building, digital acquisition, and consumer demand for health and wellness products. Investors watch user growth, gross margin, and whether the company can build a sustainable consumer franchise.

## Landscape Position

Mangoceuticals is outside biotech and belongs in the consumer health / digital health bucket. Its stock is driven more by brand execution and customer acquisition than by drug catalysts.

## Future Catalysts

- Mangoceuticals’ catalysts are its men’s-health products, consumer marketing, and any update that shows the brand can keep growing. The story is mainly a consumer-demand one.

## Recent News
- 2026-08-13 20:05 EST — [Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets](https://biopharmsignal.com/news/MGRX/mangoceuticals-inc-s-merger-partner-nuclea-energy-inc-enters-into-definitive-agr-f8cc0429) — Source: MANGOCEUTICALS
- 2026-08-06 11:00 EST — [Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure](https://biopharmsignal.com/news/MGRX/mangoceuticals-merger-partner-nuclea-energy-inc-signs-mou-with-new-mining-co-to--e01e8771) — Source: MANGOCEUTICALS
- 2026-08-05 20:05 EST — [Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development](https://biopharmsignal.com/news/MGRX/mangoceuticals-merger-partner-nuclea-energy-nuclea-executes-mou-with-utah-office-57201b51) — Source: MANGOCEUTICALS
- 2026-08-04 20:05 EST — [Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination](https://biopharmsignal.com/news/MGRX/mangoceuticals-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-min-8398ceee) — Source: MANGOCEUTICALS
- 2026-07-30 11:00 EST — [Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology](https://biopharmsignal.com/news/MGRX/mangoceuticals-announces-business-combination-agreement-with-nuclea-energy-inc-t-cef06d33) — Source: MANGOCEUTICALS